ZhangPLiWYYangSC, et al.Preventive effects of nicorandil against contrast-induced nephropathy in patients with moderate renal insufficiency undergoing percutaneous coronary intervention. Angiology. 2019;71(2):183–188. doi:10.1177/0003319719841733.
GoldenbergIMatetzkyS. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172(11):1461–71.
4.
StolkerJMMcCulloughPARaoS, et al.Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography. J Am Coll Cardiol. 2010;55(14):1433–40.
5.
ShamsMDehghanPHosseinpanahF. Metformin and intravascular contrast media: what to do in patients receiving both: a narrative review. Novel Biomed. 2017;5(3):138–45.
6.
SigtermanTAKrasznaiAGSnoeijsMGHeijboerRSchurinkGWBouwmanLH. Contrast induced nephropathy and long-term renal decline after percutaneous transluminal angioplasty for symptomatic peripheral arterial disease. Eur J Vasc Endovasc Surg. 2016;51(3):386–93.
7.
IbrahimTAEl-MawardyRHEl-SerafyASEl-FekkyEM. Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease. Cardiovasc Revasc Med. 2017;18(5):315–9.
8.
NadkarniGNKonstantinidisIPatelA, et al.Trimetazidine decreases risk of contrast-induced nephropathy in patients with chronic kidney disease: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol Ther. 2015;20(6):539–46.
9.
YeZLuHSuQ, et al.Clinical effect of trimetazidine on prevention of contrast-induced nephropathy in patients with renal insufficiency: an updated systematic review and meta-analysis. Medicine (Baltimore). 2017;96(9):e6059.
10.
Abdel-SalamOMMohammedNASleemAA. The effects of trimetazidine on lipopolysaccharide-induced oxidative stress in mice. EXCLI J. 2011;10:162–72.
11.
WilliamsFMTandaKKusMWilliamsTJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol. 1993;22(6):828–33.
